Company / Cash & Equivalents
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$63.7M
FY2025
5-year range
$55.4M / $460.7M
FY2021-FY2025
Trend
+15.1%
vs FY2024
Sector context
#127 of 148
Health Care
What the data says
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s cash & equivalents of $64M is lower than 86% of companies in the Health Care sector (FY2025). Cash & Equivalents returned to growth in FY2025 after 3 years of decline, reaching $64M.
Based on SEC 10-K filings.
$64M in FY2025 with a 5-year CAGR of -4.8%.
Declined from $180M to $64M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -41.9%
- 5-Year CAGR
- -4.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 148This company $63.7M Sector average $1.2B
▼
-94.6% below sector average
Key checks
Key Insights
- 5-year CAGR of -4.8%, indicating a declining trend.
- In FY2025, cash & equivalents increased 15.1% year-over-year.
- Ranks #127 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $63.7M | +15.1% |
| FY2024 | $55.4M | -69.2% |
| FY2023 | $179.9M | -44.7% |
| FY2022 | $325.1M | -29.4% |
| FY2021 | $460.7M | +464.5% |
| FY2020 | $81.6M | +175.5% |
| FY2019 | $29.6M | +57.2% |
| FY2018 | $18.8M | +14.2% |
| FY2017 | $16.5M | -1.5% |
| FY2016 | $16.8M | -36.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026